WEKO3
アイテム
{"_buckets": {"deposit": "fd3969c2-5de0-4899-b8bf-522b2401d473"}, "_deposit": {"created_by": 2, "id": "14099", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "14099"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00014099", "sets": ["9"]}, "author_link": ["50692", "50691"], "item_2_alternative_title_19": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "Antigen specific treatment for the inhibition and remission of type 1 diabetes"}]}, "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2008-12-31", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "6", "bibliographicPageEnd": "439", "bibliographicPageStart": "432", "bibliographicVolumeNumber": "31", "bibliographic_titles": [{"bibliographic_title": "日本臨床免疫学会会誌"}, {"bibliographic_title": "Japanese Journal of Clinical Immunology", "bibliographic_titleLang": "en"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "近年,抗CD3抗体などの生物学的製剤を中心に,ヒト1型糖尿病の分野においても,疾患の治癒・寛解を目指し治療法の開発研究がすすめられているが,安全性,経済性などの問題を抱えている.インスリンは,ヒト,NODマウスの1型糖尿病発症に関連した主要自己抗原である.膵島浸潤T細胞に反応せず,しかも,血糖降下作用を維持する変異インスリン(B鎖16位残基アラニン置換)のみを発現するNODマウスでは,インスリン自己抗体が発現せず,糖尿病も発症しない.NODマウスに,poly I:Cをアジュバントに,インスリンB鎖ペプチドを皮下投与すると,制御性T細胞だけでなく,攻撃側のeffector細胞も膵島内に誘導する.一方,インスリンB鎖16, 19位残基を置換したアナログペプチドを,コレラトキシンをアジュバントに経鼻投与すると,強力な糖尿病発症の抑制と高血糖からの寛解を誘導した.このように,膵島抗原を用いた免疫学的治療法は,投与ルートやアジュバント,補助療法に改良を加え,制御性T細胞を優位に誘導することより,今後,ヒト1型糖尿病において,安全な発症阻止,寛解誘導の治療法となる可能性がある.", "subitem_description_type": "Abstract"}, {"subitem_description": "Treatment with anti-CD3 antibodies appears promising to preserve residual beta-cell function in recent onset type 1 diabetes although many patients had therapy related adverse events. Insulin is an important islet antigen and autoimmunity to insulin may be central to disease pathogenesis of type 1 diabetes in man and NOD mouse. Evidence is strongest for the NOD mouse model, where blocking immune responses to insulin by amino acid substitution at positions B: 16, prevents diabetes. Insulin can be used to immunologically prevent diabetes of NOD mice, however, insulin-based preventive immunoregulation of diabetes in man is not yet possible. Treatment of NOD mice with insulin B-chain peptide and poly I: C, a Toll-like receptor 3 ligand, induces the pathogenic T cells as well as regulatory T cells and recruits them into the islets. Intranasal treatment with insulin B-chain analogue peptide with amino acid substitutions at positions B: 16 and 19 prevented the progression to diabetes and induced remission from hyperglycemia when co-administered with a mucosal adjuvant cholera toxin. Thus, an antigenic peptide vaccination with an alternative adjuvant or route might induce antigen-specific regulatory cell populations rather than pathogenic T cells. We believe that such an improved antigen specific therapy could provide more efficient and safer disease suppression and remission for human type 1 diabetes.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "日本臨床免疫学会会誌, 31(6), pp.432-439; 2008", "subitem_description_type": "Other"}]}, "item_2_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "50692", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Abiru, Norio"}]}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "日本臨床免疫学会"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.2177/jsci.31.432", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "Copyright (c) 2008 日本臨床免疫学会"}]}, "item_2_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00357971", "subitem_source_identifier_type": "NCID"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "09114300", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "13497413", "subitem_source_identifier_type": "ISSN"}]}, "item_2_text_62": {"attribute_name": "出版者別言語", "attribute_value_mlt": [{"subitem_text_value": "The Japan Society for Clinical Immunology"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "阿比留, 教生"}], "nameIdentifiers": [{"nameIdentifier": "50691", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "JJCI31_432.pdf", "filesize": [{"value": "984.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 984200.0, "url": {"label": "JJCI31_432.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/14099/files/JJCI31_432.pdf"}, "version_id": "1267fd06-0149-450f-9b1a-069e0b2dfebd"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "type 1 diabetes", "subitem_subject_scheme": "Other"}, {"subitem_subject": "prevention", "subitem_subject_scheme": "Other"}, {"subitem_subject": "autoantigen", "subitem_subject_scheme": "Other"}, {"subitem_subject": "insulin peptide", "subitem_subject_scheme": "Other"}, {"subitem_subject": "regulatory T cells", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "1型糖尿病の発症阻止と寛解誘導", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "1型糖尿病の発症阻止と寛解誘導"}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/24074", "pubdate": {"attribute_name": "公開日", "attribute_value": "2010-10-05"}, "publish_date": "2010-10-05", "publish_status": "0", "recid": "14099", "relation": {}, "relation_version_is_last": true, "title": ["1型糖尿病の発症阻止と寛解誘導"], "weko_shared_id": 2}
1型糖尿病の発症阻止と寛解誘導
http://hdl.handle.net/10069/24074
http://hdl.handle.net/10069/2407482068440-84dc-47f5-aa59-d6612280a56c
名前 / ファイル | ライセンス | アクション |
---|---|---|
JJCI31_432.pdf (984.2 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2010-10-05 | |||||
タイトル | ||||||
タイトル | 1型糖尿病の発症阻止と寛解誘導 | |||||
言語 | ||||||
言語 | jpn | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | type 1 diabetes | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | prevention | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | autoantigen | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | insulin peptide | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | regulatory T cells | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
阿比留, 教生
× 阿比留, 教生 |
|||||
著者別名 | ||||||
姓名 | Abiru, Norio | |||||
その他のタイトル | ||||||
その他のタイトル | Antigen specific treatment for the inhibition and remission of type 1 diabetes | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | 近年,抗CD3抗体などの生物学的製剤を中心に,ヒト1型糖尿病の分野においても,疾患の治癒・寛解を目指し治療法の開発研究がすすめられているが,安全性,経済性などの問題を抱えている.インスリンは,ヒト,NODマウスの1型糖尿病発症に関連した主要自己抗原である.膵島浸潤T細胞に反応せず,しかも,血糖降下作用を維持する変異インスリン(B鎖16位残基アラニン置換)のみを発現するNODマウスでは,インスリン自己抗体が発現せず,糖尿病も発症しない.NODマウスに,poly I:Cをアジュバントに,インスリンB鎖ペプチドを皮下投与すると,制御性T細胞だけでなく,攻撃側のeffector細胞も膵島内に誘導する.一方,インスリンB鎖16, 19位残基を置換したアナログペプチドを,コレラトキシンをアジュバントに経鼻投与すると,強力な糖尿病発症の抑制と高血糖からの寛解を誘導した.このように,膵島抗原を用いた免疫学的治療法は,投与ルートやアジュバント,補助療法に改良を加え,制御性T細胞を優位に誘導することより,今後,ヒト1型糖尿病において,安全な発症阻止,寛解誘導の治療法となる可能性がある. | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Treatment with anti-CD3 antibodies appears promising to preserve residual beta-cell function in recent onset type 1 diabetes although many patients had therapy related adverse events. Insulin is an important islet antigen and autoimmunity to insulin may be central to disease pathogenesis of type 1 diabetes in man and NOD mouse. Evidence is strongest for the NOD mouse model, where blocking immune responses to insulin by amino acid substitution at positions B: 16, prevents diabetes. Insulin can be used to immunologically prevent diabetes of NOD mice, however, insulin-based preventive immunoregulation of diabetes in man is not yet possible. Treatment of NOD mice with insulin B-chain peptide and poly I: C, a Toll-like receptor 3 ligand, induces the pathogenic T cells as well as regulatory T cells and recruits them into the islets. Intranasal treatment with insulin B-chain analogue peptide with amino acid substitutions at positions B: 16 and 19 prevented the progression to diabetes and induced remission from hyperglycemia when co-administered with a mucosal adjuvant cholera toxin. Thus, an antigenic peptide vaccination with an alternative adjuvant or route might induce antigen-specific regulatory cell populations rather than pathogenic T cells. We believe that such an improved antigen specific therapy could provide more efficient and safer disease suppression and remission for human type 1 diabetes. | |||||
書誌情報 |
日本臨床免疫学会会誌 en : Japanese Journal of Clinical Immunology 巻 31, 号 6, p. 432-439, 発行日 2008-12-31 |
|||||
出版者 | ||||||
出版者 | 日本臨床免疫学会 | |||||
出版者別言語 | ||||||
The Japan Society for Clinical Immunology | ||||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 09114300 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 13497413 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN00357971 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.2177/jsci.31.432 | |||||
権利 | ||||||
権利情報 | Copyright (c) 2008 日本臨床免疫学会 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 日本臨床免疫学会会誌, 31(6), pp.432-439; 2008 |